Status:
TERMINATED
Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease
Lead Sponsor:
The Second Affiliated Hospital of Chongqing Medical University
Conditions:
Respiratory Function Tests
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
Studies have shown that intravenous infusion and nebulized dexmedetomidine can improve lung function in mechanically ventilated patients, including those with preoperative COPD, exerting lung protecti...
Detailed Description
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that seriously endangers the physical and mental health of patients. Surgical patients with COPD will increase the risk of ...
Eligibility Criteria
Inclusion
- Patients with diagnosed COPD who are scheduled to undergo elective surgery (FEV1/FVC ratio\< 0.70)
- Patients with mild, moderate, and severe COPD (FEV1≥30% predicted)
- Age ≥ 40 years old, ≤ 80 years old
- American Society of Anesthesiologists (ASA) Physical Situation Grading I-III
- Able to cooperate with the experiment, voluntarily participate and be able to understand and sign the informed consent form
Exclusion
- Obese patients (BMI\>28 kg/m2)
- Patients with grade 3 hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg)
- Patients with myocardial infarction and shock in the past 3 months
- Patients with unstable angina pectoris with NYHA heart function grade III or IV in the last 4 weeks
- Tachycardia (heart rate \>120 beats/min), bradycardia (heart rate \<45 beats/min), and degree II or III atrioventricular block
- Patients with severe or uncontrolled bronchial asthma, pulmonary infection, bronchiectasis, thoracic malformation, pneumothorax, hemothorax, giant pulmonary bulla, and massive hemoptysis in the last 4 weeks
- Pulmonary artery pressure ≥60 mmHg
- Patients with Child B or C liver function
- Patients with stage 4 or 5 chronic kidney disease
- Patients with hyperthyroidism and pheochromocytoma
- Patients with seizures requiring medication
- Pregnant women
- Patients with tympanic membrane perforation
- Patients allergic to dexmedetomidine;
- For any reason, it is not possible to cooperate with the study or the researcher considers it inappropriate to be included in this experiment
Key Trial Info
Start Date :
October 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06207331
Start Date
October 28 2023
End Date
June 30 2024
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400000